Kestra Medical Technologies, Ltd. (KMTS) Stock Forecast
KMTS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $30.29 average of analyst targets
- Upside to target
- +11.2% from the latest close
- Next earnings
- December 10, 2026 EPS estimate $-0.61
- 52-week range
- $17.87 – $28.68
KMTS analyst ratings
8 analystsNumber of analysts at each rating.
KMTS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KMTS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Oct '26) | −$0.60 | −$0.61 | −$0.60 | −$0.45 | −34.6% | 2 |
| Next quarter (Jan '27) | −$0.57 | −$0.58 | −$0.57 | −$0.40 | −42.3% | 2 |
| Current fiscal year (FY2027) | −$2.45 | −$2.46 | −$2.44 | −$1.71 | −43.4% | 2 |
| Next fiscal year (FY2028) | −$2.06 | −$2.06 | −$2.05 | −$2.45 | +16.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KMTS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Oct '26) | $32.0M | $31.9M | $32.1M | +41.9% | 8 |
| Next quarter (Jan '27) | $35.4M | $35.0M | $35.6M | +44.3% | 8 |
| Current fiscal year (FY2027) | $140.9M | $140.7M | $141.0M | +48.1% | 8 |
| Next fiscal year (FY2028) | $195.9M | $190.2M | $200.5M | +39.0% | 8 |
KMTS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KMTS revenue: reported and forecast
KMTS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Oct '26) | −$0.55 | −$0.61 | −$0.61 | −$0.60 | −$0.60 | +11.0% | 2 up · 0 down |
| Next quarter (Jan '27) | −$0.55 | −$0.56 | −$0.56 | −$0.57 | −$0.57 | +4.5% | 0 up · 1 down |
| Current fiscal year (FY2027) | −$2.14 | −$2.31 | −$2.31 | −$2.31 | −$2.45 | +14.5% | 0 up · 2 down |
| Next fiscal year (FY2028) | −$1.41 | −$2.02 | −$2.02 | −$2.06 | −$2.06 | +45.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KMTS earnings surprises
Reported EPS vs the consensus estimate for the last 7 quarters; KMTS beat in 3 of 7.
What analysts expect from KMTS
8 analysts cover Kestra Medical Technologies; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $30.29, 11.2% above the latest close of $27.24. Analysts expect earnings of −$2.45 per share for FY2027, −43.4% from a year earlier. For FY2028 the average estimate is −$2.06 per share on revenue of $195.9 million. Kestra Medical Technologies beat the EPS estimate in 3 of the last 7 quarters.
Related: KMTS income statement, KMTS key metrics, KMTS chart. See the KMTS stock overview for the latest quote and news.
KMTS forecast FAQ
What is Kestra Medical Technologies's price target?
The average analyst price target for Kestra Medical Technologies is $30.29, 11.2% above the latest close of $27.24.
Is Kestra Medical Technologies a buy, hold or sell?
Of 8 analysts covering Kestra Medical Technologies, 5 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kestra Medical Technologies's EPS forecast?
Analysts forecast −$2.45 per share for FY2027 (range −$2.46 to −$2.44); for FY2028 the estimate is −$2.06.
What is Kestra Medical Technologies's revenue forecast?
The average revenue estimate for FY2027 is $140.9 million, growth of 48.1%; for FY2028 it is $195.9 million.
When does Kestra Medical Technologies report earnings?
Kestra Medical Technologies is expected to report results for the quarter ending October 31, 2026 on December 10, 2026; the EPS estimate is $-0.61.
Does Kestra Medical Technologies usually beat earnings estimates?
Kestra Medical Technologies reported EPS at or above the analyst estimate in 3 of the last 7 quarters.